Proprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's disease

Basit Öğe Kaydı
dc.contributor.authorAydogan Baykara, Rabia
dc.contributor.authorYilmaz, Pinar Diydem
dc.contributor.authorGoktepe, Mevlut Hakan
dc.contributor.authorKadiyoran, Cengiz
dc.contributor.authorOgul, Mustafa
dc.contributor.authorKucuk, Adem
dc.contributor.authorCumhur Cure, Medine
dc.date.accessioned2024-02-23T14:20:29Z
dc.date.available2024-02-23T14:20:29Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractObjectives The incidence of cardiovascular disease is increased in patients with Behcet's disease (BD). Proprotein convertase subtilisin/kexin type 9 (PCSK9) causes the acceleration of atherosclerosis. We aimed to investigate whether there is a relationship between PCSK9 with carotid artery intima-media thickness (cIMT), a marker of subclinical atherosclerosis, and BD disease activity. Methods Fifty-eight patients with BD and 58 age-, gender-, and body mass index (BMI)-matched healthy control subjects were included in the study. The disease activity of the patients was estimated. Individuals' cIMT values were measured, and PCSK9 levels were studied. Results Patients with BD' cIMT (0.51 +/- 0.1 vs 0.41 +/- 0.1 mm, p < .001) and PCSK9 (623.2 +/- 101.7 +/- 10.1 vs 528.3 +/- 242.7 ng/ml, p = .007), values were significantly higher than the control group. In stepwise regression analysis, there was an independent relationship between cIMT with PCSK9 (beta = 0.179, p < .050). There was no independent relationship between disease activities with PCSK9. Based on the ROC curve analysis, the PCSK9 optimal cutoff value for cIMT was 595.1 ng/ml, sensitivity 66.7%, specificity 64.7% (AUC = 0.672; 95% CI: 0.530-0.815, p = .040). Conclusion There is a strong independent association between subclinical atherosclerosis and PCSK9 in patients with BD. There may be no independent association between PCSK9 and disease activity.en_US
dc.identifier.doi10.1080/10641963.2022.2071921
dc.identifier.endpage486en_US
dc.identifier.issn1064-1963
dc.identifier.issn1525-6006
dc.identifier.issue5en_US
dc.identifier.pmid35502687en_US
dc.identifier.scopus2-s2.0-85130829033en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage480en_US
dc.identifier.urihttps://doi.org/10.1080/10641963.2022.2071921
dc.identifier.urihttps://hdl.handle.net/20.500.12452/13173
dc.identifier.volume44en_US
dc.identifier.wosWOS:000790170400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofClinical And Experimental Hypertensionen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectProprotein Convertase Subtilisinen_US
dc.subjectKexin Type 9 (Pcsk9)en_US
dc.subjectBehcet'sen_US
dc.subjectCarotid Artery Intima-Media Thickness (Cimt)en_US
dc.subjectAtherosclerosisen_US
dc.titleProprotein convertase subtilisin/kexin type 9 is associated with atherosclerosis in patients with Behcet's diseaseen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu